Skip to main content
SpringerLink
Log in

Hyperuricemic Nephropathy

  • Chapter
Therapy of Renal Diseases and Related Disorders

  • 181 Accesses

Abstract

Clinical relationships between uric acid and the human kidney have long been a topic of perennial interest (1). In this chapter we shall review the different types of renal involvement caused by uric acid or urate, and summarize the available treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Steele TH: Urate excretion in man, normal and gouty. In: WN Kelley, IM Weiner, eds, Uric Acid. Handbook of Experimental Pharmacology, Vol 51. Springer-Verlag, Berlin, pp 257–286, 1978.

    Google Scholar 

  2. Rieselbach RE, Bentzel CJ, Cotlove E, Frei E III, Freireich J: Uric acid excretion and renal function in the acute hyperuricemic of leukemia. Am J Med 37:876–884, 1964.

    Article  Google Scholar 

  3. Conger JD: Acute uric acid nephropathy. Semin Nephrol 1:69–74, 1981.

    CAS  Google Scholar 

  4. Wilcox WR, Khalaf A, Weinberger A, Kippen I, Klinenberg JR: Solubility of uric acid and monosodium urate. Med Biol Eng Comput 10:522–531, 1972.

    CAS  Google Scholar 

  5. Finlayson B, Smith A: Stability of the first dissociable proton of uric acid. J Chem Eng Data 19:94–97, 1974.

    Article  CAS  Google Scholar 

  6. Yü T-F, Gutman A: Uric acid nephrolithiasis in gout: Predisposing factors. Ann Intern Med 67:1133–1148, 1967.

    PubMed  Google Scholar 

  7. Conger JD, Falk SA, Guggenheim SJ, Burke TJ: A micro-puncture study of the early phase of acute urate nephropathy. J Clin Invest 58:681–689, 1976.

    Article  PubMed  CAS  Google Scholar 

  8. Emmerson BT, Row PG: An evaluation of the pathogenesis of the gouty kidney. Kidney Int 8:65–71, 1975.

    Article  PubMed  CAS  Google Scholar 

  9. Jenkins P, Rieselbach RE: Unique characteristics of the mechanism for reabsorption of filtered versus secreted urate (abstract). Proc Am Soc Clin Invest 36A, 1974.

    Google Scholar 

  10. Passwell J, Boichis H, Cohen BE: Hyperuricemic nephropathy. Am J Dis Child 120:154–156, 1970.

    PubMed  CAS  Google Scholar 

  11. Kanwar F, Maraligod J: Leukemic urate nephropathy. Arch Pathol 99:467–472, 1975.

    PubMed  CAS  Google Scholar 

  12. Merrill D, Jackson H: The renal complications of leukemia. N Engl J Med 228:271–276, 1943.

    Article  Google Scholar 

  13. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL: Acute tumor lysis syndrome. Am J Med 68:486–491, 1980.

    Article  PubMed  CAS  Google Scholar 

  14. Tsokos GC, Balow JE, Spiegel RJ, Magrath, IT: Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine 60:218–229, 1981.

    Article  PubMed  CAS  Google Scholar 

  15. Crittenden DR, Ackerman GL: Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med 137:97–99, 1977.

    Article  PubMed  CAS  Google Scholar 

  16. Ultmann JE: Hyperuricemia in disseminated neoplastic disease other than lymphomas and leukemias. Cancer 15: 122–129, 1962.

    Article  PubMed  CAS  Google Scholar 

  17. Emmerson BT, Thompson L: The spectrum of hypoxanthi-neguanine phosphoribosyl transferase deficiency. Q J Med 42:423–440, 1973.

    PubMed  CAS  Google Scholar 

  18. Bennett WM, Van Zee BE, Hutchings R, Cohen LH, Norby LH, Champion C, Spargo B, Selby T: Acute renal failure from ticrynafen. N Engl J Med 301:1179–1181, 1979.

    Article  PubMed  CAS  Google Scholar 

  19. Wolfe SM: Suprofen-induced transient flank pain and renal failure. Engl J Med 316:1025, 1987.

    Article  CAS  Google Scholar 

  20. Suprofen labelling revised. FDA Drug Bulletin 16;15–16, 1986.

    Google Scholar 

  21. Ahmadian Y, Lewy P: Possible urate nephropathy of the newborn infant as a cause of transient renal insufficiency. J Pediatr 91:96–100, 1977.

    Article  PubMed  CAS  Google Scholar 

  22. Warren DJ, Leitch AG, Leggett RJE: Hyperuricemic acute renal failure after epileptic seizures. Lancet 2:385–387, 1975.

    Article  PubMed  CAS  Google Scholar 

  23. Holland P, Holland N: Prevention and management of acute hyperuricemia in childhood leukemia. J Pediatr 72:358–366, 1972.

    Google Scholar 

  24. Yolken RH, Miller DR: Hyperuricemia and renal failure — presenting manifestations of occult hematologic malignancies. J Pediatr 89:775–777, 1976.

    Article  CAS  Google Scholar 

  25. Lear H, Oppenheimer GD: Anuria following radiation therapy in leukemia. JAMA 143:806–807, 1950.

    CAS  Google Scholar 

  26. Watts RWE, Watkins PJ, Mathias JQ: Allopurinol and acute uric acid nephropathy. B Med J 1:205–208, 1966.

    Article  CAS  Google Scholar 

  27. Kritzler RA: Anuria complicating the treatment of leukemia. Am J Med 25:532–538, 1958.

    Article  PubMed  CAS  Google Scholar 

  28. Alsarraf D, Reese L: Management of acute renal failure due to marked hyperuricemia. Can Med Assoc J 106:352–354, 1972.

    PubMed  CAS  Google Scholar 

  29. Howorth PJN, Zilva JF: Determination of uric acid levels in uraemia by enzymatic and colorimetric techniques. J Clin Pathol 21:192–195, 1968.

    Article  PubMed  CAS  Google Scholar 

  30. Caraway WT: Non-urate chromogens in body fluids. Clin Chem 15:720–726, 1969.

    PubMed  CAS  Google Scholar 

  31. Prien EL, Prien EL Jr: Composition and structure of urinary stone. Am J Med 45:654–672, 1968.

    Article  PubMed  CAS  Google Scholar 

  32. Kelton J, Kelley WN, Holmes EW: A rapid method for the diagnosis of acute uric acid nephropathy. Arch Intern Med 138:612–615, 1978.

    Article  PubMed  CAS  Google Scholar 

  33. Tangsanga K, Boonwichit D, Lekhakula A, Sitprija V: Urine uric acid and urine creatinine ratio in acute renal failure. Arch Intern Med 144:934–937, 1984.

    Article  Google Scholar 

  34. Kanfer A, Richet G, Roland J, Chatelet F: Extreme hyperphosphatemia causing acute anuric nephrocalcinosis in lymphosarcoma. B Med J 1:1320, 1979.

    Article  CAS  Google Scholar 

  35. Conger JD, Falk SA: Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 59:127–128, 1978.

    Google Scholar 

  36. Higenbottam T, Ogg CS, Saxton HM: Acute renal failure from the use of acetazolamide (Diamox). Postgrad Med J 54:127–128, 1978.

    Article  PubMed  CAS  Google Scholar 

  37. Barry KG, Hunter RH, Davis TE, Crosby WA: Acute uric acid nephropathy. Arch Intern Med 111:452–459, 1963.

    PubMed  CAS  Google Scholar 

  38. Handa SP: Acute renal failure in association with hyperuricemia. South Med J 64:676–678, 1971.

    Article  PubMed  CAS  Google Scholar 

  39. Anderson RJ, Linas SL, Berns As, Henrich WL, Miller TR, Gabow PA, Schrier RW: Non-oliguric acute renal failure. N Engl J Med 296:1134–1138, 1977.

    Article  PubMed  CAS  Google Scholar 

  40. Schrier RW: Acute renal failure. Kidney Int 15:205–216, 1979.

    Article  PubMed  CAS  Google Scholar 

  41. DeConti RC, Calabresi P: Use of Allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 274:481–486, 1966.

    Article  PubMed  CAS  Google Scholar 

  42. Bard PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK, Little AS: Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 283:354–357, 1970.

    Article  Google Scholar 

  43. Albin A, Stephens BG, Hirata T, Wilson K, Williams HE: Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt’s lymphoma treated with chemotherapy and allopurinol. Metabolism 21:771–778, 1972.

    Article  Google Scholar 

  44. Elion GB: Allopurinol and other inhibitors of urate synthesis. In: WN Kelley, IM Weiner, eds, Uric Acid. Handbook of Experimental Pharmacology, Vol 51. Springer-Verlag, Berlin, pp 485–514, 1978.

    Google Scholar 

  45. Edwards NL, Recker D, Airozo D, Fox IH: Enhanced purine salvage during allopurinol therapy: An important pharmacologic property in humans. J Lab Clin Med 98:673–682, 1981.

    PubMed  CAS  Google Scholar 

  46. Hande KR, Perini F, Putterman G, Elin R: Hyperxanthinemia inteferes with serum uric acid determinations by the uricase method. Clin Chem 25:1492–1494, 1979.

    PubMed  CAS  Google Scholar 

  47. Kann HE Jr, Wells JH, Gallelli JF, Schein PS, Cooney DA, Smith ER, Seegmiller JE, Carbone PP: The development and use of an intravenous preparation of allopurinol. Am J Med Sci 256:53–63, 1968.

    Article  PubMed  CAS  Google Scholar 

  48. Hande K, Noone R, Stone W: Severe allopurinol toxicity description and guildines for prevention in patients with renal insufficiency. Am J Med 76:47–56, 1984.

    Article  PubMed  CAS  Google Scholar 

  49. Elion GB, Yü T-F, Gutman AB, Hitchings GH: Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 45:69–77, 1968.

    Article  PubMed  CAS  Google Scholar 

  50. Kantor G: Toxic epidermal necrolysis, azotemia, and death after allopurinol therapy. JAMA 212:478–479, 1970.

    Article  PubMed  CAS  Google Scholar 

  51. Simmonds HA, Cameron JS, Morris GS, Davies PM: Allopurinol in renal failure and the tumour lysis syndrome. Clin Chim Acta 160:189–195, 1986.

    Article  PubMed  CAS  Google Scholar 

  52. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG: Ann Intern Med 95:588–590, 1981.

    PubMed  CAS  Google Scholar 

  53. Utsinger P: Allopurinol hypersensitivity: Granular deposition of IgM at the dermal-epidermal junction. Am J Med 61:287–294, 1976.

    Article  PubMed  CAS  Google Scholar 

  54. Hande K, Reed E, Chabner B: Allopurinol kinetics. Clin Pharm Ther 23:598–605, 1978.

    CAS  Google Scholar 

  55. Appelbaum SJ, Mayersohn M, Dorr RT, Perrier D: Allopurinol kinetics and bioavailability. Cancer Chemother Pharmacol 8:93–98, 1982.

    Article  PubMed  CAS  Google Scholar 

  56. Berlinger WG, Park GD, Spector R: The effect of dietary protein on the clearance of allopurinol and oxypurinol. N Engl J Med 313:771–776, 1985.

    Article  PubMed  CAS  Google Scholar 

  57. Friedman H, Grasela T: Adenine arabinoside and allopurinol: Possible adverse drug interaction. N Engl J Med 304:423, 1981.

    Article  PubMed  CAS  Google Scholar 

  58. Kjellstrand CM, Campbell DC, von Haritzsch B, Buselmeier TJ: Hyperuricemic acute renal failure. Arch Intern Med 133;349–359, 1974.

    Article  PubMed  CAS  Google Scholar 

  59. Steinberg SM, Galen MM, Lazarus JM, Lowrie EG, Hampers CL, Jaffe N: Hemodialysis for acute anuric uric acid nephropathy. Am J Dis Child 130:956–958, 1975.

    Google Scholar 

  60. Maher JF, Ruth CE, Schreiner GE: Hyperuricemia complicating leukemia. Arch Intern Med 123:198–200, 1969.

    Article  PubMed  CAS  Google Scholar 

  61. Deger G. Waggoner R: Peritoneal dialysis in acute uric acid nephropathy. Mayo Clin Proc 47:189–192, 1972.

    PubMed  CAS  Google Scholar 

  62. Greger R, Lang F, Deetjen P: Handling of allantoin by the rat kidney, clearance and micropuncture data. Pflügers Arch 357:201–207, 1975.

    Article  CAS  Google Scholar 

  63. Zittoon R, Dauchy F, Teillaud C, Barthelemy M, Bouchard P: Le traitment des hyperuricémies en hématologie par l’unst-oxydase et l’allopurinol. Ann Med Interne 127:479–482, 1976.

    Google Scholar 

  64. Feuillu A, Herve JP, Pogamp PL, Garre M, Chevet D: Traitement de l’hyperuricémie secondaire de i’insuffisance rénale chronique per uricolyse enzymatique. Thérapie 35: 734–749, 1980.

    Google Scholar 

  65. Brogard JM, Stahl A, Stahl J: Enzymatic uricolysis and its use in therapy. In: WN Kelly, IM Weiner, eds, Uric Acid, Handbook of Experimental Pharmacology, Vol 51. Springer-Verlag, Berlin, pp 515–524, 1978.

    Google Scholar 

  66. Abuchowski A, Karp D, Davis FF: Reduction of plasma urate levels in the cokerel with polyethylene glycol-uricase. J Pharmacol Exp Ther 219:352–354, 1981.

    PubMed  CAS  Google Scholar 

  67. Davis S, Park YK: Hypouricaemic effect of polyethylene glycol modified urate oxidase. Lancet 2:281–283, 1981.

    Article  PubMed  CAS  Google Scholar 

  68. Fitzgerlad RH, Wallace KM, Baker A: Acute obstructive uric acid nephropathy after treatment of neoplastic adenopathy. South Med J 74:424–426, 1981.

    Article  Google Scholar 

  69. Bedrna J, Polcak J: Alcuter harnleiter verschluss nach bestrahlung chronischer leukämien mit röntgenstrahlen. Med Klin 25:1700–1701, 1929.

    Google Scholar 

  70. Kravitz SC, Diamond HD, Craver LF: Uremia complicating leukemia chemotherapy. JAMA 146:1595–1597, 1951.

    CAS  Google Scholar 

  71. Eason AA, Sharlip ID, Spaulding JT: Dissolution of bilateral uric acid calculi causing anuria. JAMA 240:670–671, 1978.

    Article  PubMed  CAS  Google Scholar 

  72. Simmonds HA, Warren DJ, Cameron JS, Potter CF, Farebrother DA: Familial gout and renal failure in young women. Clin Nephrol 14;176–182, 1980.

    PubMed  CAS  Google Scholar 

  73. Coe FL: Nephrolithiasis Pathogenesis and Treatment. Yearbook Medical Publishers, Chicago, pp 95–115, 1978.

    Google Scholar 

  74. Simkin PA, Hoover PL, Paxson CS, Wilson WF: Uric acid excretion: Quantitative assessment from spot, midmorning serum and urine samples. Ann Intern Med 91:44–47, 1979.

    PubMed  CAS  Google Scholar 

  75. Wortmann RL, Fox IH: Limited value of uric acid to creatinine ratios in estimating acid excretion. Ann Intern Med 93:822–825, 1980.

    PubMed  CAS  Google Scholar 

  76. Rieselbach RE, Sorensen LB, Shelp WD, Steele TH: Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med 73:359–366, 1970.

    PubMed  CAS  Google Scholar 

  77. Steele TH, Boner G: Origins of the uricosuric response. J Clin Invest 51:1368–1375, 1973.

    Article  Google Scholar 

  78. Jacobs DR: The coronary drug project research group: Serum uric acid: Its association with other risk factors and with mortality in coronary heart disease. J Chron Dis 29: 557–569, 1976.

    Article  Google Scholar 

  79. Viozzi FJ, Bluhm GB, Riddle JM: Gout and arterial thrombosis. Henry Ford Med J 20:119–214, 1972.

    Google Scholar 

  80. Talbott JH, Terplan KL: The kidney in gout. Medicine 38:405–462, 1960.

    Google Scholar 

  81. Barlow K, Beilin L: Renal disease in primary gout. J Med 37:79–98, 1968.

    CAS  Google Scholar 

  82. Modern F, Meister L: The kidney of gout, a clinical entity. Med Clin North Am 36:941–952, 1952.

    Google Scholar 

  83. Linnane J, Barry A, Emmerson B: Urate deposits in the renal medulla. Nephron 29:216–222, 1981.

    Article  PubMed  CAS  Google Scholar 

  84. Yü T-F: Cystic diseases of the kidney and gout. Arch Intern Med 138:1609, 1978.

    Article  PubMed  Google Scholar 

  85. Thompson GR, Weiss JJ, Goldman RT, Rigg GA: Familial occurrence of hyperuricemia, gout and medullary cystic disease. Arch Intern Med 138:1614–1617, 1978.

    Article  PubMed  CAS  Google Scholar 

  86. Yü T-F, Berger L. Impaired renal function in gout, its association with hypertensive vascular disease and intrinsic renal disease. Am J Med 72:95–100, 1982.

    Article  PubMed  Google Scholar 

  87. Campion E, Glynn R, Delabry M. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 82:421–426, 1987.

    Article  PubMed  CAS  Google Scholar 

  88. Brand F, McGee D, Kannel W, Stokes J, Castell W. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epid 121:11–18, 1985.

    CAS  Google Scholar 

  89. Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand 668(Suppl):49–59, 1982.

    CAS  Google Scholar 

  90. Massari P, Usa C, Barnes R, Poxigikas P, Weller J. Familial hyperuricemia and renal disease. Arch Intern Med 140: 680–684, 1980.

    Article  PubMed  CAS  Google Scholar 

  91. Richmond J, Kincaid-Smith P, Whitworth J, Becker G. Familial gout and renal failure. Arch Dis Child 56:699–704, 1981.

    Article  Google Scholar 

  92. Foley RJ, Weinman EJ: Review: Urate nephropathy. Am J Med Sci 288:208–211, 1984.

    Article  PubMed  CAS  Google Scholar 

  93. Kelley WN: Pharmacologic approach to the maintenance of urate homeostasis. Nephron 14:99–115, 1975.

    Article  PubMed  CAS  Google Scholar 

  94. Gutman AB: Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol Chemother 4:91–142, 1966.

    Article  CAS  Google Scholar 

  95. Reese OG Jr, Steele TH: Renal transport of urate during diuretic-induced hypouricemia. Am J Med 60:973–979, 1976.

    Article  PubMed  CAS  Google Scholar 

  96. Wallace SL, Ertel NH: Pharmacology of drugs used in treatment of acute gout. In: WN Kelley, IM Weiner, eds, Uric Acid, Handbook of Experimental Pharmacology, Vol 51. Springer-Verlag, Berlin, pp 525–556, 1978.

    Google Scholar 

  97. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M: Colchicine myopathy and neuropathy. N Engl J Med 316:1562–1568, 1987.

    Article  PubMed  CAS  Google Scholar 

  98. Steele TH: Diuretic-induced-induced hyperuricacemia. In: WN Kelley, ed, Crystal-Induced Arthropathies. Clinics in Rheumatic Diseases. Saunders, London, pp 37–50, 1977.

    Google Scholar 

  99. Manuel MA, Steele TH: Changes in renal urate handling after prolonged thiazide treatment. Am J Med 57:741–746, 1974.

    Article  PubMed  CAS  Google Scholar 

  100. Hall AP, Barry PE, Dawber TR, McNamara PM: Epidemiology of gout and hyperuricemia: A long-term population study. Am J Med 42:27–37, 1967.

    Article  PubMed  CAS  Google Scholar 

  101. Fessel WJ, Siegelaub AB, Johnson ES: Correlates and consequences of asymptomatic hyperuricemia. Arch Intern Med 132:44–54, 1973.

    Article  PubMed  CAS  Google Scholar 

  102. Fessel WJ: High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 68:401–404, 1980.

    Article  PubMed  CAS  Google Scholar 

  103. Cannon PJ, Symchych PS, DeMartini FE: The distribution of urate in human and primate kidney. Proc Soc Exp Biol Med 129:278–285, 1968.

    PubMed  CAS  Google Scholar 

  104. Verger D, Leroux-Robert C, Ganter P, Richet G: Les tophus goutteux de la medullaire rénale des urémiques chroniques. Nephron 4:356–370, 1967.

    Article  PubMed  CAS  Google Scholar 

  105. Östberg Y: Renal urate deposits in chronic renal insufficiency. Acta Med Scand 183:197–201, 1968.

    Article  PubMed  Google Scholar 

  106. Fessel WJ: Renal outcomes of gout and hyperuricemia. Am J Med 67:74–82, 1979.

    Article  PubMed  CAS  Google Scholar 

  107. Yü T-F, Berger L: Renal disease in primary gout: A study of 253 gout patients with proteinuria. Semin Arthritis Rheum 4:293–305, 1975.

    Article  PubMed  Google Scholar 

  108. Berger L, Yü T-F: Renal function in gout: IV. An analysis of 525 gouty subjects including long-term follow-up studies. Am J Med 59:605–613, 1975.

    Article  PubMed  CAS  Google Scholar 

  109. Liang MH, Fries JF: Asymptomatic hyperuricemia: The case for conservative management. Ann Intern Med 88:666–670, 1978.

    PubMed  CAS  Google Scholar 

  110. Kelley W, Fox I. Gout and related disorders of purine metabolism. In: W Kelley, E Harris, S Ruddy, C Sledge, ed, Textbook of Rheumatology, 2nd. WB Saunders, Philadelphia pp 1359–1358, 1985.

    Google Scholar 

  111. Loeb JN: The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15:189–192, 1972.

    Article  PubMed  CAS  Google Scholar 

  112. Smilo RP, Beisel WR, Forsham PH: Reversal of thiazide-induced transient hyperuricemia by uricosuric agents. N Engl J Med 267:1225–1227, 1962.

    Article  PubMed  CAS  Google Scholar 

  113. Smith WE, Steele TH: The hyperuricemic nephropathies. In: WN Suki, SG Massry, eds, Therapy of Renal Diseases and Related Disorders, 1st ed. Martinus Nijhoff, Boston, pp 327–333, 1984.

    Google Scholar 

Download references

Authors
  1. Edward R. Ahrens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas H. Steele
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, The Methodist Hospital, Houston, Texas, USA

    Wadi N. Suki

  2. Division of Nephrology, University of Southern California, Los Angeles, California, USA

    Shaul G. Massry

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Kluwer Academic Publishers

About this chapter

Cite this chapter

Ahrens, E.R., Steele, T.H. (1991). Hyperuricemic Nephropathy. In: Suki, W.N., Massry, S.G. (eds) Therapy of Renal Diseases and Related Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0689-4_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-0689-4_31

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8027-9

  • Online ISBN: 978-1-4613-0689-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation